Matrix stiffness induces epithelial–mesenchymal transition and promotes chemoresistance in pancreatic cancer cells

Increased matrix rigidity associated with the fibrotic reaction is documented to stimulate intracellular signalling pathways that promote cancer cell survival and tumour growth. Pancreatic cancer is one of the stiffest of all human solid carcinomas and is characterised by a remarkable desmoplastic reaction. Here we use mouse models, genetically engineered to recapitulate human pancreatic cancer, and several pancreatic cancer cell lines as a model to investigate the effect of matrix stiffness in epithelial–mesenchymal transition (EMT) and resistance to chemotherapeutics. We found that recapitulation of the fibrotic rigidities found in pancreatic cancer tissues promote elements of EMT, including increases in vimentin expression, decreases in E-cadherin expression, nuclear localisation of β-catenin, YAP and TAZ and changes in cell shape towards a mesenchymal phenotype. We also report that stiffness induces chemoresistance to paclitaxel, but not to gemcitabine, both commonly used therapeutics, suggesting that environmental rigidity underlies an aspect of chemoresistance.

[1]  F. Ciardiello,et al.  NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice , 2016, BMC Cancer.

[2]  Huamin Wang,et al.  Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. , 2009, Cancer research.

[3]  Xiaocan Guo,et al.  Integration of mechanical and chemical signals by YAP and TAZ transcription coactivators , 2013, Cell & Bioscience.

[4]  Prasenjit Dey,et al.  Genetics and biology of pancreatic ductal adenocarcinoma , 2006, Genes & development.

[5]  Simon C. Potter,et al.  A Genome-Wide Association Search for Type 2 Diabetes Genes in African Americans , 2012, PLoS ONE.

[6]  V. Weaver,et al.  The extracellular matrix modulates the hallmarks of cancer , 2014, EMBO reports.

[7]  A. Maitra,et al.  Genetics and pathology of pancreatic cancer. , 2006, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[8]  G. Charras,et al.  Experimental validation of atomic force microscopy-based cell elasticity measurements , 2011, Nanotechnology.

[9]  R. DePinho,et al.  Genetics and biology of pancreatic ductal adenocarcinoma. , 2006, Genes & development.

[10]  P. Janmey,et al.  Substrate stiffness regulates solubility of cellular vimentin , 2014, Molecular biology of the cell.

[11]  Ueli Aebi,et al.  The nanomechanical signature of breast cancer. , 2012, Nature nanotechnology.

[12]  Alfonso Bellacosa,et al.  Epithelial–mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways , 2005, Oncogene.

[13]  Sirio Dupont Role of YAP/TAZ in mechanotransduction , 2011 .

[14]  P. Whittaker,et al.  Collagen and picrosirius red staining: a polarized light assessment of fibrillar hue and spatial distribution , 2005 .

[15]  R. Hruban,et al.  Pancreatic cancer , 2011, The Lancet.

[16]  Kun-Liang Guan,et al.  The emerging roles of YAP and TAZ in cancer , 2015, Nature Reviews Cancer.

[17]  H. Richardson,et al.  Tissue growth and tumorigenesis in Drosophila: cell polarity and the Hippo pathway. , 2017, Current opinion in cell biology.

[18]  E. Neilson,et al.  Biomarkers for epithelial-mesenchymal transitions. , 2009, The Journal of clinical investigation.

[19]  Sandra J Shefelbine,et al.  BoneJ: Free and extensible bone image analysis in ImageJ. , 2010, Bone.

[20]  Xiang-Dong Fu,et al.  Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling , 2012, Cell.

[21]  Caroline H. Diep,et al.  Down-Regulation of Yes Associated Protein 1 Expression Reduces Cell Proliferation and Clonogenicity of Pancreatic Cancer Cells , 2012, PloS one.

[22]  Caroline H. Diep,et al.  Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer , 2015, Clinical Cancer Research.

[23]  M. Hollingsworth,et al.  P-selectin expression in a metastatic pancreatic tumor cell line (SUIT-2). , 1997, Cancer research.

[24]  C. Chen,et al.  Acquisition of epithelial–mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells , 2014, British Journal of Cancer.

[25]  B. Melichar,et al.  Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer , 2016, Cancer Chemotherapy and Pharmacology.

[26]  Jingwu Xie,et al.  Promising molecular mechanisms responsible for gemcitabine resistance in cancer , 2015, Genes & diseases.

[27]  S. Bicciato,et al.  The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.

[28]  L. Bujanda,et al.  Mouse models of pancreatic cancer. , 2012, World journal of gastroenterology.

[29]  Anna B. Osipovich,et al.  Pancreas-specific Cre driver lines and considerations for their prudent use. , 2013, Cell metabolism.

[30]  J. Iredale,et al.  Type I Collagen Promotes the Malignant Phenotype of Pancreatic Ductal Adenocarcinoma , 2004, Clinical Cancer Research.

[31]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[32]  M. Greene,et al.  Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and chronic pancreatitis , 2015, Scientific Reports.

[33]  K. Guan,et al.  The Hippo-YAP pathway: new connections between regulation of organ size and cancer. , 2008, Current opinion in cell biology.

[34]  M. Karin,et al.  A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis , 2015, Genes & development.

[35]  Jason D. Fowler,et al.  Kinetic Investigation of the Inhibitory Effect of Gemcitabine on DNA Polymerization Catalyzed by Human Mitochondrial DNA Polymerase* , 2008, Journal of Biological Chemistry.

[36]  M. Hidalgo,et al.  The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer , 2013, Clinical Cancer Research.

[37]  M. Biffoni,et al.  TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells , 2014, Oncogene.

[38]  Y Quijano,et al.  Stromal disrupting effects of nab-paclitaxel in pancreatic cancer , 2013, British Journal of Cancer.

[39]  E. Karamitopoulou Role of Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Is Tumor Budding the Missing Link? , 2013, Front. Oncol..

[40]  D. Tuveson,et al.  nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. , 2012, Cancer discovery.

[41]  V. LeBleu,et al.  EMT Program is Dispensable for Metastasis but Induces Chemoresistance in Pancreatic Cancer , 2015, Nature.

[42]  Cynthia A. Reinhart-King,et al.  Tensional homeostasis and the malignant phenotype. , 2005, Cancer cell.

[43]  Albert C. Chen,et al.  Matrix stiffness drives Epithelial-Mesenchymal Transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction pathway , 2015, Nature Cell Biology.

[44]  B. R. Bass,et al.  3D collagen alignment limits protrusions to enhance breast cancer cell persistence. , 2014, Biophysical journal.

[45]  Richard G. Posner,et al.  Desmoplasia and chemoresistance in pancreatic cancer , 2012 .

[46]  J. Vandekerckhove,et al.  The phalloidin binding site of F‐actin. , 1985, The EMBO journal.

[47]  Agnes G Loeffler,et al.  Periductal stromal collagen topology of pancreatic ductal adenocarcinoma differs from that of normal and chronic pancreatitis , 2015, Modern Pathology.

[48]  A. Schetter,et al.  Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer , 2016, Oncotarget.

[49]  E. Mini,et al.  Cellular pharmacology of gemcitabine. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  C. Farah,et al.  Epithelial to mesenchymal transition (EMT) biomarkers--E-cadherin, beta-catenin, APC and Vimentin--in oral squamous cell carcinogenesis and transformation. , 2012, Oral oncology.

[51]  Mikala Egeblad,et al.  Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling , 2009, Cell.

[52]  Manuel Hidalgo,et al.  Addressing the challenges of pancreatic cancer: future directions for improving outcomes. , 2015, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[53]  A. E. del Río Hernández,et al.  Quantitative analysis of 3D extracellular matrix remodelling by pancreatic stellate cells , 2016, Biology Open.

[54]  G. Halder,et al.  The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment , 2013, Nature Reviews Drug Discovery.

[55]  Elvi Hayani,et al.  HUBUNGAN ANTARA KASUS MALARIA DENGAN KONDISI SANITASI RUMAH TEMPAT TINGGAL DI PUSKESMAS PASAR MANNA KABUPATEN BENGKULU SELATAN , 2018, Naturalis: Jurnal Penelitian Pengelolaan Sumber Daya Alam dan Lingkungan.

[56]  Xiao-Jun Ma,et al.  Role of three‐dimensional matrix stiffness in regulating the chemoresistance of hepatocellular carcinoma cells , 2015, Biotechnology and applied biochemistry.

[57]  Aude Michel,et al.  Mechanical induction of the tumorigenic β-catenin pathway by tumour growth pressure , 2015, Nature.

[58]  M. Imamura,et al.  Analysis of E-, N-Cadherin, α-, β-, and γ-Catenin Expression in Human Pancreatic Carcinoma Cell Lines , 2005, Pancreas.

[59]  J. Shea,et al.  Phenotype and Genotype of Pancreatic Cancer Cell Lines , 2010, Pancreas.

[60]  Christine A Iacobuzio-Donahue,et al.  Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular-fibrosis and tumor progression , 2016, Nature Medicine.

[61]  M. Barbacid,et al.  Genetically engineered mouse models of pancreatic adenocarcinoma , 2013, Molecular oncology.

[62]  Alexander A. Fingerle,et al.  The role of stroma in pancreatic cancer: diagnostic and therapeutic implications , 2012, Nature Reviews Gastroenterology &Hepatology.

[63]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.